Ferroptosis in cardiac hypertrophy and heart failure. 2023

Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
Department of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang 110122, China.

Heart failure has become a public health problem that we cannot avoid choosing to face in today's context. In the case of heart failure, pathological cardiac hypertrophy plays a major role because of its condition of absolute increase in ventricular mass under various stresses. Ferroptosis, it could be defined as regulatory mechanisms that regulate cell death in the absence of apoptosis in iron-dependent cells. This paper introduces various new research findings on the use of different regulatory mechanisms of cellular ferroptosis for the treatment of heart failure and cardiac hypertrophy, providing new therapeutic targets and research directions for clinical treatment. The role and mechanism of ferroptosis in the field of heart failure has been increasingly demonstrated, and the relationship between cardiac hypertrophy, which is one of the causes of heart failure, is also an area of research that we should focus on. In addition, the latest applications and progress of inducers and inhibitors of ferroptosis are reported in this paper, updating the breakthroughs in their fields.

UI MeSH Term Description Entries
D006332 Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES. Cardiac Hypertrophy,Enlarged Heart,Heart Hypertrophy,Heart Enlargement,Cardiac Hypertrophies,Enlargement, Heart,Heart Hypertrophies,Heart, Enlarged,Hypertrophies, Cardiac,Hypertrophies, Heart,Hypertrophy, Cardiac,Hypertrophy, Heart
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000079403 Ferroptosis A form of REGULATED CELL DEATH initiated by oxidative perturbations of the intracellular microenvironment that is under constitutive control by glutathione peroxidase 4 and can be inhibited by iron chelators and lipophilic antioxidants. Oxytosis
D016923 Cell Death The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability. Death, Cell
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
August 2007, Current treatment options in cardiovascular medicine,
Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
February 2013, Journal of molecular and cellular cardiology,
Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
December 2019, JACC. Basic to translational science,
Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
February 2022, Cells,
Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
June 2019, Journal of the American Heart Association,
Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
January 2008, Environmental health and preventive medicine,
Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
February 1964, The American journal of physiology,
Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
July 2005, Current medicinal chemistry. Cardiovascular and hematological agents,
Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
May 2004, Journal of investigative medicine : the official publication of the American Federation for Clinical Research,
Kuo Zhang, and Xin-Miao Tian, and Wei Li, and Li-Ying Hao
January 2011, Current pharmaceutical design,
Copied contents to your clipboard!